Table of Contents
The Scandinavian pharmaceutical market outlook to 2013
Executive Summary 12
Scandinavia – An overview 12
Healthcare in Scandinavia 13
The pharmaceutical industry in Scandinavia 14
Key players in the Scandinavian pharmaceutical market 15
An overview of leading pipeline compounds 16

Chapter 1 Scope and methodology 18
Scope 18
Methodology 18

Chapter 2 Scandinavia – An overview 20
Summary 20
Introduction 21
Population profile 22
Disease burden 23
Macroeconomic comparison of countries 27
Infrastructure 28
Healthcare Spend 30
Pharmaceutical sales growth 30

Chapter 3 Healthcare in Scandinavia 34
Summary 34
Introduction 35
Pharmaceutical marketing authorization in the EEA 37
The policy environment – Sweden 38
The policy environment – Finland 41
The policy environment – Denmark 45
The policy environment – Norway 47
Parallel trade in Scandinavia 50

Chapter 4 The pharmaceutical industry in Scandinavia 54
Summary 54
Introduction 55
Key Events 57
Economic threats to EU health budgets 57
Structural changes in the pharmaceutical industry 57
Increasing licensing deal values 58
Increasing importance of the emerging markets 59
Therapy area analysis 59
Therapy area sales forecast 60
Sweden 62
Finland 65
Denmark 69
Norway 72
Leading brands 76
Leading Scandinavian brands sales forecast 80
Sweden 81
Finland 84
Denmark 86
Norway 88
Leading players 90
Leading players sales forecast 92
Sweden 93
Finland 95
Denmark 97
Norway 99

Chapter 5 Key players of the Scandinavian pharmaceutical market 102
Summary 102
Introduction 103
Analysis of the leading Scandinavian market players 105
Pfizer 105
Overview 105
Sales focus by leading drug classes 106
Marketed product portfolio 109
Pfizer’s pipeline focus 111
Strategic growth analysis 112
AstraZeneca 115
Overview 115
Sales focus by leading drug classes 115
Marketed product portfolio 119
AstraZeneca’s pipeline focus 121
Strategic growth analysis 121
Novartis 123
Overview 123
Marketed product portfolio 125
Novartis’s pipeline focus 127
Strategic growth analysis 128
GSK 129
Overview 129
GSK’s pipeline focus 134
Strategic growth analysis 135
Johnson & Johnson 136
Overview 136
Marketed product portfolio 138
J&J’s pipeline focus 140
Strategic growth analysis 140
Leading Scandinavian pharmaceutical and biotechnology companies 141
Active Biotech 141
BioInvent 142
Strategic collaborations 142
Pipeline 143
Biotie Therapies 144
Diamyd 144
Pronova BioPharma 145

Chapter 6 An overview of leading pipeline compounds 148
Summary 148
Introduction 149
Leading drugs in development 150
Profiles of key pipeline products 151
Drugs in registration 151
Zactima 151
Axitinib 154
Paliperidone palmitate 156
Drugs in phase III clinical studies 158
Laquinimod 158
Diamyd 159
Eprotirome 161
Promacta 162
Menveo 163
Xarelto 165
Pipeline Forecast 167

Chapter 7 Scandinavian pharmaceutical market outlook – Summary findings 170
An attractive market: 170
Resistors to growth in Scandinavia 171

Chapter 8 Appendix 174
IMS Data 174
Anatomical Therapeutic Classification (ATC) 174
C: Cardiovascular system 174
N: Nervous system 174
A: Alimentary tract and metabolism 174
L: Antineoplastic and immunomodulating agents 175
J: General anti-infectives systemic 175
R: Respiratory system 175
M: Musculo-skeletal system 175
G: Genito-urinary system and sex hormones 175
B: Blood and blood forming organs 176
D: Dermatologicals 176
T: Diagnostic agents 176
H: Systemic hormonal preparations 176
S: Sensory organs 176
V: Various 176
Licensing status as per IMS Health 177
Original brand 177
Other brand 177
Licensed brand 177
Patent N/A brands 177
Unbranded/ generic product 178
Glossary 179
Index 181

List of Figures
Figure 2.1: Demographic profile of Scandinavian countries 23
Figure 2.2: Comparison of healthcare expenditure across Scandinavian countries 30
Figure 2.3: GDP growth versus pharmaceutical sales growth, 2006–2007 31
Figure 4.4: Scandinavian pharmaceutical market share by country, 2007 56
Figure 4.5: Scandinavian pharmaceutical market sales by therapy area, US$m, 2007 60
Figure 4.6: Top ten sub-therapy areas in the Swedish pharmaceutical market, 2007 ($m) 63
Figure 4.7: Top ten sub–therapy areas in the Finnish pharmaceutical market, 2007 ($m) 67
Figure 4.8: Top ten sub–therapy areas in the Danish pharmaceutical market, 2007 ($m) 71
Figure 4.9: Top ten sub–therapy areas in the Norwegian pharmaceutical market, 2007 ($m) 75
Figure 5.10: Market share of leading players in the Scandinavian market, 2007 104
Figure 5.11: Pfizer's Scandinavian market sales by therapy area, 2007, $m 106
Figure 5.12: AstraZeneca's Scandinavian market sales by therapy area, 2007, $m 116
Figure 5.13: Novartis's Scandinavian market sales by therapy area, 2007 123
Figure 5.14: GSK's Scandinavian market sales by therapy area, 2007 130
Figure 5.15: J&J's Scandinavian market sales by therapy area, 2007 136
Figure 6.16: Leading late-stage R&D products, 2008 150
Figure 6.17: Scandinavian markets' pipeline of biotechnology products by stage of development, 2008 151

List of Tables
Table 2.1: Forecast epidemiology of common disorders in Sweden, 2007–2013 24
Table 2.2: Forecast epidemiology of common disorders in Finland, 2007–2013 25
Table 2.3: Forecast epidemiology of common disorders in Denmark, 2007–2013 26
Table 2.4: Forecast epidemiology of common disorders in Norway, 2007–2013 27
Table 3.5: Reimbursement of pharmaceutical expenditure in Denmark 46
Table 3.6: Rates of reduction on annual sale of pharmaceutical products 49
Table 4.7: Scandinavian pharmaceutical market sales by ATC code, US$m, 2007–2013 61
Table 4.8: Sweden’s pharmaceutical market by therapy area sales, US$m, 2007 62
Table 4.9: Finland’s pharmaceutical market by therapy area sales, 2007, ($m) 65
Table 4.10: Denmark’s pharmaceutical market by therapy area sales, 2007 69
Table 4.11: Norway’s pharmaceutical market by therapy area sales, 2007 73
Table 4.12: Leading brands in the Scandinavian pharmaceutical market, 2007 76
Table 4.13: Leading brands sales forecast, 2007–13 80
Table 4.14: Leading brands in the Swedish pharmaceutical market, 2007 81
Table 4.15: Leading brands in the Finnish pharmaceutical market, 2007 84
Table 4.16: Leading brands in the Danish pharmaceutical market, 2007 86
Table 4.17: Leading brands in the Norwegian pharmaceutical market, 2007 88
Table 4.18: Leading companies in the Scandinavian pharmaceutical market, 2007 90
Table 4.19: Leading companies in the Scandinavian pharmaceutical market, sales forecast 2007– 2013 92
Table 4.20: Leading companies in the Swedish pharmaceutical market, 2007 93
Table 4.21: Leading companies in the Finnish pharmaceutical market, 2007 95
Table 4.22: Leading companies in the Danish pharmaceutical market, 2007 97
Table 4.23: Leading companies in the Norwegian pharmaceutical market, 2007 99
Table 5.24: Pfizer’s leading brands in Scandinavia, 2007 109
Table 5.25: AstraZeneca’s leading brands in Scandinavia, 2007 119
Table 5.26: Novartis’s leading brands in Scandinavia, 2007 125
Table 5.27: GSK’s leading brands in Scandinavia, 2007 132
Table 5.28: J&J’s leading brands in Scandinavia, 2007 138
Table 5.29: BioInvent´s major collaborations 143
Table 6.30: An overview of Zactima 152
Table 6.31: An overview of axitinib 154
Table 6.32: An overview of Paliperidone palmitate 157
Table 6.33: An overview of Laquinimod 158
Table 6.34: An overview of Diamyd 160
Table 6.35: An overview of Eprotirome 161
Table 6.36: An overview of Promacta 162
Table 6.37: An overview of Menveo 164
Table 6.38: An overview of Xarelto 165
Table 6.39: Forecast sales of pipeline compounds, 2007–2013 167